^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HB0045

    i
    Associations

    News

    Trials
    Company:
    Zhejiang Huahai Pharma
    Drug class:
    CD73 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control. (PubMed, Nat Commun)
    HB0045 is a 1:1 mixture of two humanized monoclonal IgG1 antibodies (mAbs), HB0038 and HB0039. In various animal models of syngeneic and xenograft tumors, HB0045 inhibits tumor growth more potently than the single mAbs. Collectively, our findings provide functional and structural insights into the mechanism of a CD73-targeting antibody cocktail.
    Journal
    |
    CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    CD73 expression
    |
    HB0045
    over1year
    A Study of HB0045 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=71, Recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    HB0045
    over1year
    A Study of HB0045 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=71, Not yet recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
    New P1/2 trial • Metastases
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    HB0045
    over1year
    A Study of HB0045 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=71, Not yet recruiting, Huabo Biopharm Co., Ltd.
    New P1/2 trial • Metastases
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    HB0045